

Phase 3 Study of Nemtabrutinib Plus Venetoclax vs Venetoclax and Rituximab in Second Line+ Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Estado Reclutando	Tipo de Participantes No aportado	Rangos de Edad Mayores de 64 , Adultos (18-64 años)
Género Ambos	Fases Fase III	Participantes esperados 383
Resultados Sin resultados	Bajo nivel intervención No	Enfermedad rara No
Cobertura geográfica Sin determinar	Ámbitos del ensayo tratamiento, seguridad, eficacia, farmacocinética, farmacodinamica	Terapia avanzada NO

Información

Identificador 2022-501560-17-01 (CTIS)	Cod. Protocolo MK-1026-010
--	--------------------------------------

Área terapéutica
Enfermedades [C] - Cáncer [C04]

Enfermedad investigada
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Título Científico
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

Justificación

No aportado

Objetivo Principal

1. Part 1: To evaluate the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax
 2. Part 2: To compare nemtabrutinib + venetoclax to VR with respect to PFS per 2018 iwCLL criteria, as assessed by BICR
-

Variables de Evaluación Primaria

Part 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
Part 1: Number of Participants Experiencing Adverse Events (AEs)
Part 1: Number of Participants Discontinuing Study Treatment Due to AEs
Part 2: Progression-Free Survival (PFS) per the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by Blinded Independent Central Review (BICR)

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Part 2: To compare nemtabrutinib + venetoclax to VR with respect to undetectable MRD rate in bone marrow at month 14 as assessed by central laboratory
Part 2: To compare nemtabrutinib + venetoclax to VR with respect to OS
Part 2: To compare nemtabrutinib + venetoclax to VR with respect to ORR per iwCLL criteria 2018 as assessed by BICR
Part 2: To evaluate DOR per 2018 iwCLL criteria as assessed by BICR
Part 2: To evaluate the safety and tolerability of nemtabrutinib + venetoclax

Variables de Evaluación Secundaria

Part 2: Undetectable Minimal Residual Disease (MRD) Rate in Bone Marrow as Assessed by Central Laboratory
Part 2: Overall Survival (OS)
Part 2: Objective Response Rate (ORR) per iwCLL Criteria 2018 as Assessed by BICR
Part 2: Duration of Response (DOR) per iwCLL Criteria 2018 as Assessed by BICR
Part 2: Number of Participants Experiencing AEs
Part 2: Number of Participants Discontinuing Study Treatment Due to AEs

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Confirmed diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and active disease clearly documented to initiate therapy

Participants with human immunodeficiency virus (HIV) meet ALL eligibility criteria.

Participants with adequate organ function with specimens collected within 7 days before the start of study intervention.

If capable of producing sperm, participant agrees to eliminate Nemtabrutinib: 12 days, Venetoclax: 1 month (30 days), Rituximab (rituximab biosimilar: not applicable; abstains from penile-vaginal intercourse as their preferred and usual lifestyle; OR uses prescribed contraception.

Participant assigned female sex at birth is eligible to participate if not pregnant or breastfeeding and is not a person of childbearing potential (POCBP) OR is a PCBP and uses a contraceptive method that is highly effective, has a negative highly sensitive pregnancy test, and abstains from breastfeeding.

Deletion (Del) (17p) status, tumor protein 53 (TP53) mutation status, and immunoglobulin heavy chain gene (IGHV) mutation status results required before randomization for Part 2 participants only.

Relapsed or refractory to at least 1 prior available therapy.

Have at least 1 marker of disease burden.

Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.

Has a life expectancy of at least 3 months.

Has the ability to swallow and retain oral medication.

Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.

Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening.

Criterios de Exclusión

Has active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection.

Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization.

Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) within 12 months before randomization or has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids.

Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong inducers or inhibitors, or CYP3A moderate inducers

Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention.

Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.

Has known psychiatric or substance use disorder that would interfere with the participants ability to cooperate with the requirements of the study.

Participants who have not adequately recovered from major surgery or have ongoing surgical complications.

Has gastrointestinal (GI) dysfunction that may affect drug absorption.

Has known additional malignancy that is progressing or has required active treatment within the past 2 years.

Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL.

Has active infection requiring systemic therapy, such as intravenous (IV) antibiotics, during screening.

HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castlemans Disease and/or acquired

immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening.
Clinically significant cardiovascular disease.
Has known allergy/sensitivity to nemtabrutinib or contraindication to venetoclax/rituximab (or rituximab biosimilar), or any of the excipients.
Has history of severe bleeding disorders (eg, hemophilia).

Calendario

(Última actualización: 25/03/2026)

Autorización 29/11/2023	Inicio de Ensayo 18/12/2023	Inclusión Primer Paciente 29/02/2024	Interrumpido No aportado	Reiniciado No aportado
Fin de reclutamiento No aportado	Fin prematuro (España) No aportado	Fin prematuro (Global) No aportado	Fin del ensayo en España No aportado	Fin del ensayo global No aportado

Promotor

Merck Sharp & Dohme LLC United States
126 East Lincoln Avenue

Contact Person

Ima Paydarç
+16102169935
ima.paydar@merck.com

Monetary support: N/A
Tipo de promotor: Comercial

Ceim

CEIm Hospital Clínico San Carlos

C/ Doctor Martín Lagos, s/n - Ciudad Universitaria 28040 Madrid

ceic.hcsc@salud.madrid.org

917044160

Centros

Activo (18/12/2023)

Hospital Clínico Universitario De Valencia

Valencia

VALENCIA

Hematology

Activo (18/01/2024)

Hospital Universitario Quironsalud Madrid

Pozuelo De Alarcon

MADRID

Hematology

Activo (31/01/2024)

Institut Catala D'oncologia

L'hospitalet De Llobregat

BARCELONA

Hematology

Medicamentos

RITUXIMAB

SOLUTION FOR INFUSION
INTRAVENOUS INFUSION

-

Principios Activos: N/A

Experimental

RITUXIMAB

SOLUTION FOR INFUSION
INTRAVENOUS INFUSION

-

Principios Activos: N/A

Experimental

Truxima 500 mg concentrate for solution for infusion

SOLUTION FOR INFUSION
OTHER USE

Código ATC: L01FA01 - RITUXIMAB

Principios Activos: N/A

Experimental

Nemtabrutinib

TABLET
ORAL

-

Principios Activos: N/A

Experimental

Ruxience 100 mg concentrate for solution for infusion

SOLUTION FOR INFUSION
OTHER USE

Código ATC: L01XC02 - RITUXIMAB

Principios Activos: N/A

Experimental

Truxima 100 mg concentrate for solution for infusion

SOLUTION FOR INFUSION
OTHER USE

Código ATC: L01FA01 - RITUXIMAB

Principios Activos: N/A

Experimental

-
-
ORAL

Código ATC: L01XX52 - VENETOCLAX

Principios Activos: N/A

Experimental



Ruxience 500 mg concentrate for solution for infusion

SOLUTION FOR INFUSION
OTHER USE

Código ATC: L01XC02 - RITUXIMAB

Principios Activos: N/A

Experimental



Nemtabrutinib
FILM-COATED TABLET
ORAL

-

Principios Activos: N/A

Experimental

Nemtabrutinib
TABLET
ORAL

-

Principios Activos: N/A

Experimental

Nemtabrutinib
FILM-COATED TABLET
ORAL

-

Principios Activos: N/A

Experimental

Sin resultados

Phase 3 Study of Nemtabrutinib Plus Venetoclax vs Venetoclax and Rituximab in Second Line+ Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

State

Recruiting

Type of participants

Not provided

Age Ranges

Older than 64 , Adults (18-64 years)

Gender

Both

Phases

Phase III

Expected Participants

383

Results

No results

Low level of intervention

No

Rare disease

No

Geographic coverage

Undetermined

Areas of the study

treatment, safety, effectiveness,
pharmacokinetics, pharmacodynamics

Advanced therapy

NO

Information

Identifier

2022-501560-17-01 (CTIS)

Protocol Code

MK-1026-010

Therapeutic area

Diseases [C] - Cancer [C04]

Investigated Disease

Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Scientific Title

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

Rationale

Not provided

Main Objective

1. Part 1: To evaluate the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax
 2. Part 2: To compare nemtabrutinib + venetoclax to VR with respect to PFS per 2018 iwCLL criteria, as assessed by BICR
-

Primary Endpoints

- Part 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
 - Part 1: Number of Participants Experiencing Adverse Events (AEs)
 - Part 1: Number of Participants Discontinuing Study Treatment Due to AEs
 - Part 2: Progression-Free Survival (PFS) per the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by Blinded Independent Central Review (BICR)
-

Temporary moments of secondary assessment

Not provided

Secondary Objective

- Part 2: To compare nemtabrutinib + venetoclax to VR with respect to undetectable MRD rate in bone marrow at month 14 as assessed by central laboratory
 - Part 2: To compare nemtabrutinib + venetoclax to VR with respect to OS
 - Part 2: To compare nemtabrutinib + venetoclax to VR with respect to ORR per iwCLL criteria 2018 as assessed by BICR
 - Part 2: To evaluate DOR per 2018 iwCLL criteria as assessed by BICR
 - Part 2: To evaluate the safety and tolerability of nemtabrutinib + venetoclax
-

Secondary Endpoints

- Part 2: Undetectable Minimal Residual Disease (MRD) Rate in Bone Marrow as Assessed by Central Laboratory
 - Part 2: Overall Survival (OS)
 - Part 2: Objective Response Rate (ORR) per iwCLL Criteria 2018 as Assessed by BICR
 - Part 2: Duration of Response (DOR) per iwCLL Criteria 2018 as Assessed by BICR
 - Part 2: Number of Participants Experiencing AEs
 - Part 2: Number of Participants Discontinuing Study Treatment Due to AEs
-

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Confirmed diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and active disease clearly documented to initiate therapy

Participants with human immunodeficiency virus (HIV) meet ALL eligibility criteria.

Participants with adequate organ function with specimens collected within 7 days before the start of study intervention.

If capable of producing sperm, participant agrees to eliminate Nemtabrutinib: 12 days, Venetoclax: 1 month (30 days), Rituximab (rituximab biosimilar: not applicable; abstains from penile-vaginal intercourse as their preferred and usual lifestyle; OR uses prescribed contraception.

Participant assigned female sex at birth is eligible to participate if not pregnant or breastfeeding and is not a person of childbearing potential (POCBP) OR is a PCOBP and uses a contraceptive method that is highly effective, has a negative highly sensitive pregnancy test, and abstains from breastfeeding.

Deletion (Del) (17p) status, tumor protein 53 (TP53) mutation status, and immunoglobulin heavy chain gene (IGHV) mutation status results required before randomization for Part 2 participants only.

Relapsed or refractory to at least 1 prior available therapy.

Have at least 1 marker of disease burden.

Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.

Has a life expectancy of at least 3 months.

Has the ability to swallow and retain oral medication.

Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.

Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening.

Exclusion criteria

Has active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection.

Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization.

Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) within 12 months before randomization or has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids.

Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong inducers or inhibitors, or CYP3A moderate inducers

Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention.

Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.

Has known psychiatric or substance use disorder that would interfere with the participants ability to cooperate with the requirements of the study.

Participants who have not adequately recovered from major surgery or have ongoing surgical complications.

Has gastrointestinal (GI) dysfunction that may affect drug absorption.

Has known additional malignancy that is progressing or has required active treatment within the past 2 years.

Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL.

Has active infection requiring systemic therapy, such as intravenous (IV) antibiotics, during screening.

HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castlemans Disease and/or acquired

immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening.
Clinically significant cardiovascular disease.
Has known allergy/sensitivity to nemtabrutinib or contraindication to venetoclax/rituximab (or rituximab biosimilar), or any of the excipients.
Has history of severe bleeding disorders (eg, hemophilia).

Calendar

(Last Update: 25/03/2026)

Authorization 29/11/2023	Start of Trial 18/12/2023	First patient inclusion 29/02/2024	Halted Not aported	Restarted Not aported
End of recruitment Not aported	Premature end (Spain) Not aported	Premature End (Global) Not aported	Trial end (Spain) Not aported	Trial end (Global) Not aported

Sponsor

Merck Sharp & Dohme LLC United States
126 East Lincoln Avenue

Contact Person

Ima Paydarç
+16102169935
ima.paydar@merck.com

Monetary support: N/A
Sponsor type: Commercial

Ceim

CEIm Hospital Clínico San Carlos

C/ Doctor Martín Lagos, s/n - Ciudad Universitaria 28040 Madrid

ceic.hcsc@salud.madrid.org

917044160

Sites

Active (18/12/2023)

Hospital Clínico Universitario De Valencia

Valencia

VALENCIA

Hematology

Active (18/01/2024)

Hospital Universitario Quironsalud Madrid

Pozuelo De Alarcon

MADRID

Hematology

Active (31/01/2024)

Institut Catala D'oncologia

L'hospitalet De Llobregat

BARCELONA

Hematology

Medication

RITUXIMAB

SOLUTION FOR INFUSION
INTRAVENOUS INFUSION

-

Active Principles: N/A

Experimental

RITUXIMAB

SOLUTION FOR INFUSION
INTRAVENOUS INFUSION

-

Active Principles: N/A

Experimental

Truxima 500 mg concentrate for solution for infusion

SOLUTION FOR INFUSION
OTHER USE

ATC code: L01FA01 - RITUXIMAB

Active Principles: N/A

Experimental

Nemtabrutinib

TABLET
ORAL

-

Active Principles: N/A

Experimental

Ruxience 100 mg concentrate for solution for infusion

SOLUTION FOR INFUSION
OTHER USE

ATC code: L01XC02 - RITUXIMAB

Active Principles: N/A

Experimental

Truxima 100 mg concentrate for solution for infusion

SOLUTION FOR INFUSION
OTHER USE

ATC code: L01FA01 - RITUXIMAB

Active Principles: N/A

Experimental

-
-
ORAL

ATC code: L01XX52 - VENETOCLAX

Active Principles: N/A

Experimental



Ruxience 500 mg concentrate for solution for infusion

SOLUTION FOR INFUSION
OTHER USE

ATC code: L01XC02 - RITUXIMAB

Active Principles: N/A

Experimental



Nemtabrutinib
FILM-COATED TABLET
ORAL

-

Active Principles: N/A

Experimental

Nemtabrutinib
TABLET
ORAL

-

Active Principles: N/A

Experimental

Nemtabrutinib
FILM-COATED TABLET
ORAL

-

Active Principles: N/A

Experimental

No results